Inotuzumab ozogamicin, an anti-CD22–calecheamicin conjugate, for refractory and relapsed acute lymphocytic leukaemia: a phase 2 study

Authors

Keywords

Journal

Volume 13, Issue 4, Pages 403-411

Publisher

Elsevier BV

Online

2012-02-21

DOI

10.1016/s1470-2045(11)70386-2

Discuss science. Find collaborators. Network.

Join a conversation

The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.

Get Started